Danaher Corporation (DHR)
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors
Danaher (DHR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DHR crossed above the 20-day moving average, suggesting a short-term bullish trend.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core revenue gains expected in 2026.
Why Is Danaher (DHR) Down 7% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
